Literature DB >> 18695931

Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.

Claudine C Hunault1, Tjeert T Mensinga, Irma de Vries, Hermien H Kelholt-Dijkman, Jani Hoek, Maaike Kruidenier, Marianne E C Leenders, Jan Meulenbelt.   

Abstract

RATIONALE: Delta9-Tetrahydrocannabinol (THC) is the main active constituent of cannabis. In recent years, the average THC content of some cannabis cigarettes has increased up to approximately 60 mg per cigarette (20% THC cigarettes). The pharmacokinetics of THC after smoking cannabis cigarettes containing more than approximately 35 mg THC (3.55% THC cigarettes) is unknown. To be able to perform suitable exposure risk analysis, it is important to know if there is a linear relation at higher doses.
OBJECTIVES: The present study aimed to characterise the pharmacokinetics of THC, the active metabolite 11-OH-THC and the inactive metabolite THC-COOH after smoking a combination of tobacco and cannabis containing high THC doses.
MATERIALS AND METHODS: This double-blind, placebo-controlled, four-way, cross-over study included 24 male non-daily cannabis users (two to nine joints per month). Participants were randomly assigned to smoke cannabis cigarettes containing 29.3, 49.1 and 69.4 mg THC and a placebo. Serial serum samples collected over a period of 0-8 h were analysed by liquid chromatography electrospray tandem mass spectrometry. Effects on heart rate, blood pressure and 'high' feeling were also measured.
RESULTS: Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively. A large inter-individual variability in Cmax was observed. Heart rate and 'high' feeling significantly increased with increasing THC dose.
CONCLUSIONS: This study demonstrates that the known linear association between THC dose and THC serum concentration also applies for high THC doses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695931     DOI: 10.1007/s00213-008-1260-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Characterization of the absorption phase of marijuana smoking.

Authors:  M A Huestis; A H Sampson; B J Holicky; J E Henningfield; E J Cone
Journal:  Clin Pharmacol Ther       Date:  1992-07       Impact factor: 6.875

2.  Acute marijuana effects on human risk taking.

Authors:  Scott D Lane; Don R Cherek; Oleg V Tcheremissine; Lori M Lieving; Cythia J Pietras
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

3.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Effects of acute smoked marijuana on complex cognitive performance.

Authors:  C L Hart; W van Gorp; M Haney; R W Foltin; M W Fischman
Journal:  Neuropsychopharmacology       Date:  2001-11       Impact factor: 7.853

5.  Binding of (+)- and (minus)-delta-1-tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man.

Authors:  M Widman; S Agurell; M Ehrnebo; G Jones
Journal:  J Pharm Pharmacol       Date:  1974-11       Impact factor: 3.765

6.  Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol.

Authors:  L M Bornheim; J M Lasker; J L Raucy
Journal:  Drug Metab Dispos       Date:  1992 Mar-Apr       Impact factor: 3.922

7.  Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH)

Authors:  M A Huestis; J E Henningfield; E J Cone
Journal:  J Anal Toxicol       Date:  1992 Sep-Oct       Impact factor: 3.367

8.  Comparison of effects of marihuana cigarettes to three different potencies.

Authors:  M Perez-Reyes; S Di Guiseppi; K H Davis; V H Schindler; C E Cook
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

9.  Simultaneous determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy- Delta9-tetrahydrocannabinol in human plasma by high-performance liquid chromatography/tandem mass spectrometry.

Authors:  Barbora Maralikova; Wolfgang Weinmann
Journal:  J Mass Spectrom       Date:  2004-05       Impact factor: 1.982

10.  Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in serum by GC/MS using deuterated internal standards and its application to a smoking study and forensic cases.

Authors:  M R Moeller; G Doerr; S Warth
Journal:  J Forensic Sci       Date:  1992-07       Impact factor: 1.832

View more
  23 in total

1.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

2.  Marijuana use differentially affects cannabinoid receptor expression in early gestational human endometrium and placenta.

Authors:  Naveen K Neradugomma; Kaitlyn Drafton; Diana R O'Day; Michael Z Liao; Lyrialle W Han; Ian A Glass; Qingcheng Mao
Journal:  Placenta       Date:  2018-05-09       Impact factor: 3.481

3.  Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Authors:  Ryan Vandrey; Evan S Herrmann; John M Mitchell; George E Bigelow; Ronald Flegel; Charles LoDico; Edward J Cone
Journal:  J Anal Toxicol       Date:  2017-03-01       Impact factor: 3.367

Review 4.  Cannabis in sport: anti-doping perspective.

Authors:  Marilyn A Huestis; Irene Mazzoni; Olivier Rabin
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

5.  Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2019-05-02       Impact factor: 3.922

6.  Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat.

Authors:  Lauren C Harte; Diana Dow-Edwards
Journal:  Neurotoxicol Teratol       Date:  2010-05-09       Impact factor: 3.763

7.  Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Authors:  Claudine C Hunault; Tjeert T Mensinga; Koen B E Böcker; C Maarten A Schipper; Maaike Kruidenier; Marianne E C Leenders; Irma de Vries; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

8.  Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users.

Authors:  Liam Nestor; Robert Hester; Hugh Garavan
Journal:  Neuroimage       Date:  2009-07-23       Impact factor: 6.556

9.  Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.

Authors:  Claudine C Hunault; Koen B E Böcker; R K Stellato; J Leon Kenemans; Irma de Vries; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2014-05-31       Impact factor: 4.530

10.  Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice.

Authors:  Marcoita T Gilbert; Kathleen K Sulik; Eric W Fish; Lorinda K Baker; Deborah B Dehart; Scott E Parnell
Journal:  Neurotoxicol Teratol       Date:  2015-12-18       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.